← All trials
NCT04708210
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 28, 2021
- Primary completion
- May 21, 2024
- Completion date
- Aug 21, 2024
- First posted
- Jan 13, 2021
- Last posted
- May 7, 2021
- Enrollment
- 256
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Innovent Biologics (Suzhou) Co. Ltd.Lead sponsor
- Shantou UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.